Tyrosinase
drugOn this page
Also known as Human tyrosinaseMonophenol monooxygenaseTumor rejection antigen ab
Summary
Tyrosinase (CHEMBL5095345) is a phase-3 clinical-stage enzyme; indicated across 5 conditions including melanoma and cutaneous melanoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Enzyme
- Indications: 5 conditions
- Clinical trials: 27
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095345 |
| Name | Tyrosinase |
| Type | Enzyme |
| Max phase | 3 |
Also known as: Human tyrosinase, Monophenol monooxygenase, Tumor rejection antigen ab, Tyrosinase, TYROSINASE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| metastatic melanoma | 3 | MONDO:0005191 | EFO:0002617 |
| ocular melanoma | 3 | MONDO:0006325 | EFO:1000403 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 27.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 16 |
| PHASE1 | 7 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00036816 | PHASE3 | TERMINATED | Vaccine Therapy in Treating Patients With Melanoma of the Eye |
| NCT01989572 | PHASE3 | COMPLETED | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery |
| NCT00001685 | PHASE2 | COMPLETED | Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase |
| NCT00003222 | PHASE2 | COMPLETED | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00003229 | PHASE1/PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal |
| NCT00003274 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery |
| NCT00003339 | PHASE2 | COMPLETED | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00003362 | PHASE2 | COMPLETED | Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma |
| NCT00006113 | PHASE2 | TERMINATED | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00006385 | PHASE2 | COMPLETED | Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma |
| NCT00019383 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma |
| NCT00019396 | PHASE2 | COMPLETED | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer |
| NCT00020358 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Melanoma |
| NCT00031733 | PHASE2 | COMPLETED | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma |
| NCT00084656 | PHASE2 | COMPLETED | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma |
| NCT00085189 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma |
| NCT00089063 | PHASE2 | COMPLETED | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma |
| NCT00153569 | PHASE2 | UNKNOWN | Multiepitope Peptide Vaccination in Melanoma |
| NCT00334776 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| NCT00003665 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Stage IV Melanoma |
| NCT00003792 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| NCT00005633 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00005841 | PHASE1 | TERMINATED | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00025181 | PHASE1 | COMPLETED | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery |
| NCT00037037 | PHASE1 | UNKNOWN | Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma |
| NCT00698100 | PHASE1 | COMPLETED | Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines |
| NCT00006243 | Not specified | COMPLETED | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: melanoma, cutaneous melanoma, metastatic melanoma, ocular melanoma